Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Shares Outstanding (Diluted Average) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Shares Outstanding (Diluted Average) over the past 16 years, most recently at $34.8 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Diluted Average) fell 5.02% year-over-year to $34.8 million; the TTM value through May 2025 reached $34.8 million, down 5.02%, while the annual FY2025 figure was $34.8 million, 5.02% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q2 2025 was $34.8 million at Lifecore Biomedical, Inc. \De\, up from $34.1 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $36.7 million in Q2 2024 and troughed at $29.3 million in Q2 2021.
  • A 5-year average of $31.7 million and a median of $30.1 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 22.94% in 2023 and later decreased 6.91% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $29.5 million in 2021, then increased by 0.45% to $29.6 million in 2022, then rose by 22.94% to $36.4 million in 2023, then decreased by 5.6% to $34.4 million in 2024, then rose by 1.33% to $34.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for LFCR at $34.8 million in Q2 2025, $34.1 million in Q1 2025, and $34.4 million in Q4 2024.